two doctors reviewing a patient's chart

New clinical trial opens to determine safety and efficacy of PROSTVAC, nivolumab and ipilimumab in men with localized prostate cancer

A new study is now open to evaluate the safety and effectiveness of a treatment regimen that combines PROSTVAC with ipilimumab and/or nivolumab in men with localized prostate cancer who have elected to undergo surgical resection (prostatectomy).  Learn more...

Susan Gottesman receives Herbert Tabor Research Award

Posted: Apr 21, 2017

Susan Gottesman, Ph.D., Co-Chief of the Laboratory of Molecular Biology, received the 2017 Herbert Tabor Research Award from the American Society for Biochemistry and Molecular Biology (ASBMB) at the annual meeting on April 22, 2017. The award is given for excellence in biological chemistry, molecular biology and contributions to the science community.

 

Susan Gottesman receives Herbert Tabor Research Award

Hiroaki Mitsuya elected to Association of American Physicians

Posted: Apr 21, 2017

Hiroaki Mitsuya, M.D., Ph.D., Senior Investigator in the HIV and AIDS Malignancy Branch, was elected to the 2017 Association of American Physicians. Members are selected because of their pursuit and advancement of basic and clinical science and how those advances translate to clinical medicine.

 

Hiroaki Mitsuya elected to Association of American Physicians

Structural map of Kaposi sarcoma-associated herpesvirus RNA provides clues to molecular interactions

Posted: Apr 20, 2017

Scientists from CCR have generated a comprehensive structural map of Kaposi sarcoma-associated herpesvirus polyadenylated nuclear (PAN) RNA, a long non-coding RNA that helps the virus evade detection by its host’s immune system. The findings open new oppportunites to study the life cycle of this cancer-causing virus.  Learn more...

Structural map of Kaposi sarcoma-associated herpesvirus RNA provides clues to molecular interactions

Clinical trial studies a new form of vincristine in standard combination chemotherapy for children with relapsed ALL

Posted: Apr 20, 2017

A combination of chemotherapy drugs known by the regimen UK ALL R3 is one of the most successful treatments for patients with relapsed acute lymphoblastic leukemia (ALL). In this study, investigators hope to improve outcomes by combining the treatment with Marqibo, a new formulation of the drug vincristine. Learn more...

Clinical trial studies a new form of vincristine in standard combination chemotherapy for children with relapsed ALL

Center for Cancer Research plays key role in first FDA-approved drug for treatment of Merkel cell carcinoma

Posted: Apr 18, 2017

The Center for Cancer Research’s ability to rapidly deploy integrated basic and clinical research teams at a single site facilitated the rapid FDA approval of the immunotherapy drug avelumab for metastatic Merkel cell carcinoma, a rare, aggressive form of skin cancer. Learn more...

 

Center for Cancer Research plays key role in first FDA-approved drug for treatment of Merkel cell carcinoma

New clinical trial studies the use of avelumab in patients with recurrent thymoma and thymic carcinoma

Posted: Apr 18, 2017

A new study uses immunotherapy for patients whose thymoma or thymic carcinoma has progressed after standard treatments. Learn more...

New clinical trial studies the use of avelumab in patients with recurrent thymoma and thymic carcinoma

New targets for immunotherapy-based treatment of HPV-related cancers

Posted: Apr 14, 2017

Scientists at the Center for Cancer Research and three other cancer research institutions show that immunotherapy treatments that resulted in complete regression of metastatic cervical cancer largely targeted two non-viral antigens. Read more…

 

New targets for immunotherapy-based treatment of HPV-related cancers

Steve Hughes awarded 2017 Distinguished Research Career Award from The Ohio State University Center for Retrovirus Research

Posted: Apr 12, 2017

Steve Hughes, Ph.D., Chief of the Retroviral Replication Laboratory, received the 2017 Distinguished Research Career from The Ohio State University Center for Retrovirus Research on March 30, 2017. He was selected to receive this award in recognition of his substantial work on retroviruses.  Learn more...

Steve Hughes awarded 2017 Distinguished Research Career Award from The Ohio State University Center for Retrovirus Research

Pages